Christopher Whalen
About Christopher Whalen
Christopher Whalen serves as a Director at multiple companies, including DRT Holdings, Inc., Trojan Lithograph Corporation, and Mill Rock Capital, where he also holds the position of Managing Partner. He has a background in Economics and Government from Dartmouth College and specializes in investing in middle-market companies, particularly in sectors such as chemicals, materials, and packaging.
Work at Tandym Group
Christopher Whalen has served as Director at Tandym Group since 2021. His role involves overseeing various strategic initiatives within the organization. Tandym Group is known for its focus on staffing and consulting services, and Whalen's leadership contributes to its operational effectiveness.
Current Positions and Responsibilities
In addition to his role at Tandym Group, Christopher Whalen holds director positions at several companies, including DRT Holdings, Inc., Trojan Lithograph Corporation, All Packaging Company, Palmer Holland, and Venture Metals. He has been with these organizations for multiple years, focusing on strategy, operations, and portfolio management.
Education and Expertise
Christopher Whalen studied at Dartmouth College, where he earned an AB in Economics and Government from 1993 to 1997. His educational background provides a solid foundation for his extensive experience in private investment and operations across various industries.
Background in Investment and Operations
Whalen co-founded Mill Rock Capital in 2018, focusing on investing in middle-market companies in sectors such as chemicals, materials, and packaging. He has a particular interest in family-owned businesses and founder-led companies, employing a flexible investment style that includes majority equity and structured capital.
Previous Experience
Before his current roles, Christopher Whalen held various director positions at companies such as JPW Industries, Cisco Equipment, and TruckPro, LLC. He also served as an Advisory Board Member at Mason Industrial Technology and was a co-founder and investor at New York Endocrinology from 2018 to 2022.